The NSF Engineering Center for Revolutionizing Metallic Biomaterials is introducing a significant new collaborator today. Executives of InCube Labs of San Jose are at N.C. A&T to sign an agreement to work together on bringing the ERC’s technology to the medical marketplace.
InCube takes basic biomedical technology and develops medical applications that physicians can use to improve patient outcomes. InCube has spun off more than 20 companies that produce implantable devices, drug delivery combinations, and interventional devices and use novel biomaterials. That background positions it well for implementing the ERC’s novel magnesium alloys and other technology for implantable, bioresorbable medical devices.
Significance of the agreement
Dr. Leon Esterowitz of the National Science Foundation says InCube’s commercialization expertise addresses a critical gap in the way biomedical technology is developed today. Dr. Esterowitz is the NSF program director working with the ERC.
“Translating knowledge from biomedical science into clinical applications has been compared to crossing a ‘valley of death’ because of the many issues that separate the scientist at the research bench from the M.D. at the bedside,” Esterowitz says.
“Forty years ago basic and clinical research were linked in institutions such as NIH. Medical research was largely done by physician-scientists who also treated patients. That changed with the explosion of molecular biology in the 1970s. Clinical and basic research started to separate, and biomedical research departments emerged as a new discipline.